Related Experiment Video

Updated: Jun 21, 2026

Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues
08:47

Induction of Experimental Autoimmune Encephalomyelitis in Mice and Evaluation of the Disease-dependent Distribution of Immune Cells in Various Tissues

Published on: May 8, 2016

Shifting therapeutic attention in MS to osteopontin, type 1 and type 2 IFN

Lawrence Steinman1

  • 1Department of Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University, Stanford, CA 94305, USA. steinman@stanford.edu

European Journal of Immunology
|August 15, 2009
PubMed

Insights

Multiple sclerosis (MS) pathogenesis may involve osteopontin more than Th1 or Th17 pathways. Targeting osteopontin could be a novel therapeutic strategy for relapsing-remitting MS (RRMS).

Area of Science:

  • Immunology
  • Neuroscience

Background:

  • The precise immune pathways driving Multiple Sclerosis (MS) pathogenesis, specifically the roles of T helper 1 (Th1) and T helper 17 (Th17) cells, remain debated.
  • MS lesions exhibit transcriptional activity linked to Interleukin-6 (IL-6), IL-17, osteopontin, and Interferon (IFN).
  • Clinical observations show MS exacerbation with IFN-gamma administration and TNF-alpha blockade, while IL-23 inhibition failed to impact relapsing-remitting MS (RRMS).

Discussion:

  • Type 1 Interferons (IFN), particularly IFN-beta, a key therapy for RRMS, operate outside the traditional Th1/Th17 framework.
  • IFN-beta has been shown to suppress osteopontin and IL-17 production in CD4(+) T cells.
  • This suggests a potential mechanism for IFN-beta's therapeutic effect in RRMS by modulating these specific molecules.

Key Insights:

  • Osteopontin and IL-17 production in CD4(+) T cells are suppressed by IFN-beta.
  • Osteopontin may play a more critical role in RRMS pathogenesis than Th1 or Th17 cells.
  • The study highlights the importance of osteopontin in the context of MS immune responses.

Outlook:

  • Further clinical trials targeting osteopontin are warranted for RRMS treatment.
  • Investigating osteopontin as a therapeutic target could offer a new avenue for MS management.
  • Understanding the interplay between IFN-beta, osteopontin, and IL-17 is crucial for future MS therapies.

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...